Process for the preparation of shaped, compressed controlled-release
unit-dosage forms, and the compressed unit-dosage forms thus obtained
    2.
    发明授权
    Process for the preparation of shaped, compressed controlled-release unit-dosage forms, and the compressed unit-dosage forms thus obtained 失效
    用于制备成形压缩的控释单元剂型的方法以及由此获得的压缩的单位剂型

    公开(公告)号:US5840330A

    公开(公告)日:1998-11-24

    申请号:US357143

    申请日:1994-12-15

    CPC分类号: A61K9/2095 A61K9/2077

    摘要: Process for the preparation of shaped, compressed controlled-release unit-dosage forms from a therapeutic active substance exhibiting a self-retarding release that depends on the magnitude of the force used for the compression. The process gives unit-dosage forms for which the release of the active substance is highly uniform, reproducibly identical and largely linear. To achieve this, the active substance and an additive charge that inhibits or compensates for the self-retardation of its release are processed into particles in the first stage of production, so that the preliminary compressed objects made from these particles without any further additives exhibit a rapid release (in comparison with the required controlled release) over the range of the force of compression envisaged for the production of the unit-dosage form in question, after which the particles are compressed in the second stage of production with a release-retarding agent to obtain the unit-dosage forms. The invention also relates to the unit-dosage forms thus obtained.

    摘要翻译: 从治疗活性物质制备成形的,压缩的控制释放单位剂型的方法,其表现出取决于用于压缩的力的大小的自我缓解释放。 该方法给出了单位剂型,其中活性物质的释放是高度均匀的,可重复地相同的并且在很大程度上是线性的。 为了达到这个目的,在生产的第一阶段,抑制或补偿其释放的自我延迟的活性物质和添加剂被加工成颗粒,使得由这些颗粒制成的预先压制的物体没有任何其它添加剂显示出 在生产所述单位剂量形式的压缩力的范围内快速释放(与所需的控制释放相比),然后在第二阶段用释放阻滞剂压缩颗粒 以获得单位剂型。 本发明还涉及由此获得的单位剂型。

    Clodronate-containing medicaments and a process for the preparation
thereof
    3.
    发明授权
    Clodronate-containing medicaments and a process for the preparation thereof 失效
    含氯膦酸盐的药物及其制备方法

    公开(公告)号:US4859472A

    公开(公告)日:1989-08-22

    申请号:US134047

    申请日:1987-12-17

    摘要: The present invention provides a medicament containing 80 to 95% clodronate, 2 to 10% filling material and 1 to 10% lubricant.The present invention also provides a process for the production of a clodronate-containing medicament containing 80 to 95% clodronate, 2 to 10% filling material and 1 to 10% lubricant, wherein the dry components are mixed, moist granulated with an aqueous binding agent and the granulate obtained subsequently dried, a lubricant being additionally admixed with the final granulate in an amount of from 1 to 5% and the mixture thus obtained pressed into tablets or filled into capsules which have a rate of dissolving of >90% after 30 minutes.

    摘要翻译: 本发明提供含有80〜95%氯膦酸盐,2〜10%填充材料和1〜10%润滑剂的药物。 本发明还提供一种含有氯膦酸盐的药物的方法,所述药物含有80-95%的氯膦酸盐,2-10%的填充材料和1-10%的润滑剂,其中将干组分混合,用含水结合剂 然后将得到的颗粒随后干燥,将润滑剂另外与最终颗粒混合1至5%,并将所得混合物压制成片剂或填充至胶囊中,30分钟后溶解速率> 90% 。

    Composition for a stable vein compatible injectable solution of
torasemide process for the preparation and method of use
    5.
    发明授权
    Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use 失效
    用于制备和使用方法的稳定静脉相容的托拉塞米注射液的组合物

    公开(公告)号:US4861786A

    公开(公告)日:1989-08-29

    申请号:US71201

    申请日:1987-07-08

    摘要: The present invention provides an aqueous, alkaline injection solution of torasemide ready for injection, which contains a physiologically compatible alkaline buffer with a pH value of from 9.3 to 9.9 and with a buffer capacity of up to 0.1 val/liter together with an organic solvent in an amount of from 5 to 20% by weight selected from the group of polyethylene glycols with a molecular weight of from 100 to 1500, polypropylene glycols with a molecular weight of from 50 to 1000, glycerol, propylene glycol, ethanol and propanol, the torasemide being present in a concentration of from 2 to 40 mg/ml. Torasemide solutions are useful to inhibit inflammation or promote diuresis.The present invention also provides a process for the preparation of this solution, wherein torasemide is suspended in the above organic solvent brought into solution by the addition of aqueous alkali, adding the buffer and other adjuvants and adjusting the pH value to 9.3 to 9.9.

    摘要翻译: 本发明提供了一种立即注射的托拉塞米的水性碱性注射溶液,其含有pH值为9.3至9.9的生理学相容的碱性缓冲液,缓冲能力高达0.1瓦/升以及有机溶剂在 选自分子量为100至1500的聚乙二醇组,分子量为50至1000的聚丙二醇,甘油,丙二醇,乙醇和丙醇的5至20重量%的量,托拉塞米 以2至40mg / ml的浓度存在。 托拉塞米溶液可用于抑制炎症或促进利尿。 本发明还提供了一种制备该溶液的方法,其中托拉塞米通过加入碱水悬浮在上述加入溶液中的有机溶剂中,加入缓冲液和其它助剂并将PH值调节至9.3至9.9。

    Elongated, divisible tablet
    8.
    发明授权
    Elongated, divisible tablet 失效
    细长的,可分割的平板电脑

    公开(公告)号:US5562920A

    公开(公告)日:1996-10-08

    申请号:US393003

    申请日:1995-03-01

    IPC分类号: A61J3/10 A61K9/20 A61K9/44

    CPC分类号: A61K9/2072 A61J3/10

    摘要: Elongated, divisible tablet especially for pharmaceutical applications which, when the underside of the tablet is rested on a flat support, touches the support with two zones protruding from both ends of the underside of the tablet but not with the intervening zone wherein the protruding zones are formed as bulges. Such a tablet can be easily divided into two halves with one hand and picked up from a support. In addition it is easily manufactured.

    摘要翻译: PCT No.PCT / EP93 / 02218 Sec。 371 1995年3月1日 102(e)1995年3月1日PCT PCT 1993年8月19日PCT公布。 出版物WO94 / 05949 日期1994年3月17日长时间分割的片剂特别适用于制药应用,当片剂的下侧搁置在平坦的支架上时,触摸支撑件,其中两个区域从片剂下侧的两端突出,但不与中间区域 其中所述突出区域形成为凸起。 这样的平板电脑可以容易地用一只手分成两半,并从支架上拾起。 另外它很容易制造。